Back

Semaglutide for the secondary prevention of cardiovascular disease in people with overweight or obesity, but without diabetes: a cost-effectiveness analysis

31 August 2024 (18:00 - 18:30)
Organised by: Logo
Congress Presentation Part of: Mapping cardiovascular health: risk factors, interventions, and geographic insights Health Economics ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Associate Professor Adam James Nelson

VICTORIAN HEART HOSPITAL, Melbourne (Australia)

4 More presentations in this session

Presentation thumbnail
Cardiovascular risk factors and disease mortality among asian american subgroups
Doctor R. Aggarwal (Boston, US)
Abstract Slides Video
Presentation thumbnail
Mortality rate of percutaneous coronary interventions in st-segment elevation myocardial infarction patients under the public health insurance schemes of thailand
Mr S. Chumsantivut (Bangkok, TH)
Abstract Slides Video
Presentation thumbnail
Air pollution and cerebrovascular diseases - retrospective analysis of 10,486 cases of acute ischemic stroke requiring intravenous thrombolysis. A report from the EP-PARTICLES study
Mr M. Swieczkowski (Bialystok, PL)
Abstract Slides Video
Presentation thumbnail
Analyzing the economic ramifications of the broad implementation of generic prasugrel
Doctor F. Gerardo (Amadora, PT)
Abstract Slides Video

Access the full session

Session thumbnail
Mapping cardiovascular health: risk factors, interventions, and geographic insights

The Event

Event poster

ESC Congress 2024

31 August 2024 18:00 CET
You may be interested in
thumbnail
Congress Presentation
Cost-effectiveness of semaglutide for secondary prevention of cardiovascular disease in the United States
thumbnail
Congress Presentation
Potential real-world benefit of semaglutide 2.4 mg on cardiovascular outcomes in the UK based on the SELECT trial
thumbnail
Congress Presentation
Semaglutide is associated with lower risk of cardiovascular events compared with tirzepatide in patients with overweight or obesity and ASCVD and without diabetes in routine clinical practice

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources